Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Carbamic acid, [(1S)-1-(hydroxymethyl)-2-propynyl]-, 1,1-dimethylethyl ester is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

275388-05-1 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • Carbamic acid, [(1S)-1-(hydroxymethyl)-2-propynyl]-, 1,1-dimethylethyl ester

    Cas No: 275388-05-1

  • USD $ 1.9-2.9 / Gram

  • 100 Gram

  • 1000 Metric Ton/Month

  • Chemlyte Solutions
  • Contact Supplier
  • 275388-05-1 Structure
  • Basic information

    1. Product Name: Carbamic acid, [(1S)-1-(hydroxymethyl)-2-propynyl]-, 1,1-dimethylethyl ester
    2. Synonyms: Carbamic acid, [(1S)-1-(hydroxymethyl)-2-propynyl]-, 1,1-dimethylethyl ester;(S)-TERT-BUTYL (1-HYDROXYBUT-3-YN-2-YL)CARBAMATE
    3. CAS NO:275388-05-1
    4. Molecular Formula: C9H15NO3
    5. Molecular Weight: 185.2203
    6. EINECS: N/A
    7. Product Categories: N-BOC
    8. Mol File: 275388-05-1.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: Sealed in dry,Room Temperature
    8. Solubility: N/A
    9. CAS DataBase Reference: Carbamic acid, [(1S)-1-(hydroxymethyl)-2-propynyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
    10. NIST Chemistry Reference: Carbamic acid, [(1S)-1-(hydroxymethyl)-2-propynyl]-, 1,1-dimethylethyl ester(275388-05-1)
    11. EPA Substance Registry System: Carbamic acid, [(1S)-1-(hydroxymethyl)-2-propynyl]-, 1,1-dimethylethyl ester(275388-05-1)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 275388-05-1(Hazardous Substances Data)

275388-05-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 275388-05-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,7,5,3,8 and 8 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 275388-05:
(8*2)+(7*7)+(6*5)+(5*3)+(4*8)+(3*8)+(2*0)+(1*5)=171
171 % 10 = 1
So 275388-05-1 is a valid CAS Registry Number.

275388-05-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name tert-butyl N-[(2S)-1-hydroxybut-3-yn-2-yl]carbamate

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:275388-05-1 SDS

275388-05-1Relevant articles and documents

Synthesis of a Novel Rhizobitoxine-Like Triazole-Containing Amino Acid

Boibessot, Thibaut,Bénimèlis, David,Jean, Marion,Benfodda, Zohra,Meffre, Patrick

supporting information, p. 2685 - 2688 (2016/11/30)

The synthesis of the four stereoisomers of a new 1,2,3-triazole analogue of rhizobitoxine from serine is described. The key step is a Huisgen 1,3-dipolar cycloaddition on an ethynylglycine synthon.

4-Alkenyl- and 4-alkynyloxindoles

-

, (2008/06/13)

Disclosed are novel 4-alkenyl- and 4-alkynyl oxindoles having the formula and the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, a, b, and X are as defined herein. These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular cancer, more particularly, the treatment or control of breast and colon tumors. Also disclosed are pharmaceutical compositions containing the compounds of formula I and II as well as intermediates useful in the preparation of the compounds of formula I and II.

En route to optically active ethynylglycine derivatives

Meffre, Patrick,Gauzy, Laurence,Perdigues, Chantal,Desanges-Levecque, Florence,Branquet, Eric,Durand, Philippe,Le Goffic, Francois

, p. 877 - 880 (2007/10/02)

First results in the synthesis of chiral non racemic ethynylglycine derivatives from protected L-serinal are described.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 275388-05-1